The use of sodium-glucose co-transporter type II (SGLT2) inhibitors in patients with chronic heart failure against the background of type 2 diabetes mellitus


DOI: https://dx.doi.org/10.18565/pharmateca.2023.12.21-26

V.I. Petrov, O.V. Shatalova, M.S. Klykova, N.P. Stetsky

Volgograd State Medical University, Volgograd, Russia
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the risk of hospitalization for heart failure in large studies of patients with type 2 diabetes mellitus (DM2), chronic heart failure (CHF) with reduced left ventricular ejection fraction, and patients after percutaneous coronary intervention. This review analyzes the results of large randomized clinical trials that assess the effectiveness and safety of SGLT2 inhibitors in DM2 patients with varying degrees of CHF.
Keywords: empagliflozin, SGLT2 inhibitors, dapagliflozin, type 2 diabetes mellitus, heart failure
Read entire article

About the Autors

Corresponding author: Maria S. Klykova, Teaching Assistant, Professor, Department of Clinical Pharmacology and Intensive Care, Volgograd State Medical University, Volgograd, Russia; marusya8906@mail.ru


Similar Articles

Back to Content

Бионика Медиа